OABI Logo

OmniAb, Inc. (OABI) 

NASDAQ
Market Cap
$473.76M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
67 of 775
Rank in Industry
51 of 433

Largest Insider Buys in Sector

OABI Stock Price History Chart

OABI Stock Performance

About OmniAb, Inc.

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human …

Insider Activity of OmniAb, Inc.

Over the last 12 months, insiders at OmniAb, Inc. have bought $3.24M and sold $137,991 worth of OmniAb, Inc. stock.

On average, over the past 5 years, insiders at OmniAb, Inc. have bought $2.95M and sold $186,495 worth of stock each year.

Highest buying activity among insiders over the last 12 months: FOEHR MATTHEW W (Chief Executive Officer) — $9.71M.

The last purchase of 240,000 shares for transaction amount of $1.06M was made by FOEHR MATTHEW W (President and CEO) on 2024‑05‑24.

List of Insider Buy and Sell Transactions, OmniAb, Inc.

2024-05-24PurchasePresident and CEO
240,000
0.2109%
$4.42$1.06M-3.87%
2024-04-08SaleChief Legal Officer
6,954
0.0059%
$5.27$36,648-17.70%
2024-04-08SaleExecutive VP, Finance and CFO
6,954
0.0059%
$5.27$36,648-17.70%
2024-04-01SaleExecutive VP, Finance & CFO
11,849
0.0103%
$5.46$64,696-18.10%
2024-03-22PurchasePresident and CEO
225,000
0.1948%
$5.19$1.17M-13.96%
2023-12-12PurchaseChief Executive Officer
200,000
0.1722%
$5.05$1.01M-7.94%
2023-11-10PurchasePresident and CEO
95,000
0.0821%
$4.27$405,517+9.31%
2023-08-14PurchasePresident and CEO
45,000
0.0391%
$5.48$246,600-6.79%
2023-06-09PurchaseChief Executive Officer
115,000
0.1157%
$4.52$519,800+14.35%
2023-05-23Saledirector
9,000
0.0085%
$4.05$36,450+19.95%
2023-05-19Saledirector
1,000
0.0011%
$4.05$4,050+34.20%
2023-05-18Saledirector
50,000
0.05%
$3.89$194,500+32.02%
2023-05-12PurchaseChief Executive Officer
440,000
0.4311%
$3.40$1.5M+48.00%

Insider Historical Profitability

31.17%
FOEHR MATTHEW WPresident and CEO
3536665
2.9226%
$3.9270+31.17%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$42.6M6.687.86M+1.05%+$441,946.680.02
BlackRock$38.33M6.017.07M-2.96%-$1.17M<0.01
The Vanguard Group$30.97M4.865.71M+1.1%+$336,750.02<0.01
Macquarie Group$18.83M2.953.47M-2.64%-$510,032.650.02
William Blair Investment Management$18.23M2.863.36M+0.81%+$146,909.100.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.